Clinical Trials · NCT06771115

Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

Name: Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Semaglutide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Zomagen Biosciences Ltd.
Enrollment: 175
Start date: Jan 2025
Locations: 14 sites, United States
Primary endpoint: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)

View Semaglutide compound reference